Physician profile
Paul E Harvey
NPI 1669490645
$20,963.73
in general payments reported to CMS, 2019-2025
13 companies · $493 in 2025
The $493 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $185 · 2021: $149 · 2022: $19K · 2023: $668 · 2024: $145 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clerio Vision, INC | $18,900.00 | 2022 | |
| Coopervision INC. | $528.31 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $338.67 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $249.71 | 2020-2025 | Precision 1, Tryptyr, Precision7 |
| Sun Pharmaceutical Industries INC. | $212.21 | 2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $179.39 | 2019-2020 | |
| Sight Sciences, INC. | $137.75 | 2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $122.46 | 2023-2025 | Infuse, Blink Nutritears, Miebo |
| Biotissue Holdings INC. | $111.11 | 2025 | |
| Oyster Point Pharma, INC. | $21.63 | 2025 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $21.00 | 2024 | Oxervate |
| Lkc Technologies, INC. | $16.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.